This study is for adults with relapsed or refractory multiple myeloma (RRMM), a type of blood cancer. The goal is to check the safety of an investigational medication that targets a specific protein called MMSET. This is a Phase I study, meaning it is one of the first steps to learn about the medication's safety.
Key points to consider:
- Study Length and Visits: The study is divided into two parts. The first part lasts 28 days, and the second part continues based on safety results.
- Eligibility: Participants need to be 18 or older, have had at least 3 prior treatments for multiple myeloma, and meet specific medical criteria.
- Medical Requirements: Participants must have a confirmed t(4;14) test result and measurable disease. Certain previous treatments or conditions may exclude participation.
Participants will receive the investigational medication either alone or with other treatments to see how well it works and how safe it is. If you are interested, please discuss with your doctor to see if this study might be appropriate for you.
How understandable was the trial content above?
Hard to understand
Easy to understand